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cardiac four-dimensional CT (4D-CT) synchronized to the 
electrocardiogram were obtained in treatment position, using a 
prospective sequential acquisition method including the extreme 
phases of systole and diastole. On a MimVista® image 
registration workstation, dose distributions were transferred to 
the cardiac 4D-CT. The left coronary artery, left ventricle and 
heart were contoured on both phases of the cardiac cycle. The 
maximum and minimum doses to the left coronary, left ventricle 
and heart were compared using a bilateral paired Student T test.  
Results: Preliminary data from the first eight patients enrolled 
are presented. Median age was 60 years (56-71) and median 
planned dose to the left breast was 42.56 Gy (42.56-50) in 16 
fractions (16-20). For the left coronary artery, mean dose, V5 
and V20 in systole versus diastole were 6.1 Gy versus 7.9 Gy (p = 
0.02), 37% versus 48% (p = 0.02) and 10% versus 16% (p = 0.04), 
respectively. For the left ventricle, mean dose, V5 and V20 in 
systole versus diastole were 1.3 Gy versus 1.6 Gy (p = 0.005), 6% 
versus 9% (p = 0.03) and 1% versus 2% (p > 0.1), respectively. For 
the whole heart, mean dose, V5 and V20 in systole versus diastole 
were 0.9 Gy versus 1.3 Gy (p = 0.005), 21 cc versus 32 cc (p = 
0.07) and 4 cc versus 5 cc (p > 0.1), respectively. 
Conclusions: Beyond DIBH, systolic irradiation would be 
associated with a further reduction in V5, V20 and mean dose to 
the left coronary artery, as well as a reduction in V5 and mean 
dose to the left ventricle and heart as a whole. The potential 
clinical impact of this reduction as well as the feasibility of 
cardiac gated irradiation are to be further investigated. 
 
74 
INNOVATIVE APPROACH FOR GENERATING SOFT SILICONE BOLUS 
USING 3D PRINTING FOR ELECTRON TREATMENT OF SKIN CANCERS 
IN AREAS WITH IRREGULAR CONTOURS  
Kate Johnson1, Arbind Dubey1, David Sasaki1, Daniel Rickey1, 
Chad Harris2, Todd Boyer2, James Butler2, Ahmet Leylek2, Ankur 
Sharma2, Rashmi Koul2 
1University of Manitoba, Winnipeg, MB 
2CancerCare Manitoba, Winnipeg, MB 
 
Purpose: Non-melanoma skin cancers occurring in areas with 
irregular contours like the ear pose challenges in effectively 
delivering a therapeutic radiation dose using electrons. As 
electrons deliver dose at a depth, a tissue equivalent material 
called bolus must be placed on the skin so that therapeutic dose 
is delivered to the tumour. Commercially available bolus 
materials lack the ability to conform to a patient’s specific 
anatomy in areas with irregular contours. Such shortcomings can 
create air cavities between the tumour and bolus, and ultimately 
lead to treatment inaccuracy. A custom bolus can be made from 
wax, but this also has shortcomings. It is labour intensive and 
challenging to create a wax bolus with uniform specified 
thickness and minimal air gaps. As an alternative, we have 
developed a technique of generating soft silicone bolus, which 
conforms to irregular anatomy, using an optical scanner and rigid 
material 3D printer. 
Methods and Materials: Volunteer specific anatomy of the ear 
was acquired using a consumer-grade optical scanner (3D 
Systems, Sense). A three-dimensional model of each volunteer 
was exported to a mesh editing software (Autodesk, MeshMixer 
v2.9) where replica of the ear anatomy was designed. This 
replica was exported as an STL file to software controlling the 
printer (Repetier-Host), converted to gcode (Slic3r) and printed 
on a consumer-Grade 3D printer (MakerGear, M2). This replica 
served as a rigid mould for silicone rubber. The result was a soft 
bolus with one side flat and the other side perfectly fitting the 
ear. 
Results: The soft silicone bolus created by this technique 
perfectly fit the anatomy, was of desired thickness, comfortable 
to put on with no sharp edges. There were no air gaps visible. No 
air bubbles were found using x-ray imaging. Dosimetric studies 
were done on the silicone rubber and it was found acceptable to 
be used as a bolus material. 
Conclusions: Using an optical scanner and 3D printer enables us 
to create a soft, flexible silicone conformal bolus which is cost 
effective. Silicone bolus accurately fits with no air gaps and is 
better for irregular contours than a commercial or wax bolus. It 
is also better than a hard plastic 3D printed bolus for areas where 
a rigid bolus is difficult to use or causes patient discomfort. This 
approach does not require intensive training and enhances the 
patient experience as they can have an optical scan on the day 
of clinical appointment and directly come on the day of 
treatment. It also has potential to save treatment machine time 
because the setup time is anticipated to be reduced as the 
complexity of set up is greatly decreased.  
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Purpose: To determine the rates of urinary intervention for 
patients with low- and low-tier intermediate-risk prostate cancer 
treated with intraoperatively planned low dose rate prostate 
brachytherapy. 
Methods and Materials: From 2003-2012, 723 consecutive 
patients were treated with intraoperatively planned LDR 
prostate brachytherapy without external beam radiotherapy at 
our centre. Dosimetric planning targets were uniform with a goal 
of D90 prostate > 180 Gy, V150 > 74%, V200 > 37%, V140 urethra 
< 24% and V150 urethra < 3%. Patients were followed according 
to a protocol every 6 months for the first three years then 
annually. For each patient, all data were entered into a central 
database prospectively and retrospectively verified by reviewing 
a centralized electronic health record that comprehensively 
captures all interventions performed and visitations to any 
medical centre in the province of Alberta, Canada. Urinary 
interventions included cystoscopy, transurethral resection of the 
prostate, urethral dilatation or catheterization for urinary 
retention or hematuria attributable to brachytherapy. These 
patients were then isolated and compared with the remaining 
control cohort using tests of proportions and multivariate 
analysis as appropriate. 
Results: Median follow up was 7.1 years (range: 2.5 - 12.5). 
Intervention for RTOG Grade 3 toxicity was encountered in 51 
patients (7%). Cystoscopy was done in 31 patients (4.3%) for RT 
related hematuria or obstruction. TURP was performed in 14 
patients (1.9%) with a median time from implant of 20.4 months 
(range, 3-86) and dilatation for RT toxicity in six patients (0.8%) 
with a median time of 29 months (range, 20-85). Median pre-
implant volume was 37.1 cc (20.2 - 53.0) in patients having 
intervention for Grade 3 toxicity and 33.7 cc (13.2 - 66.9) in 
those without [p < 0.05]. Time from biopsy to implant, pre-
treatment AUA symptom score, PSA, clinical stage, use of 
hormones, and urethral dosimetry did not predict for urinary 
intervention in our analysis. 
Conclusions: Urinary intervention rates following 
intraoperatively planned LDR prostate brachytherapy are low 
overall at 7%. The strength of our study is the ability to review 
all hospital records in our health region to completely capture 
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